A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY
Latest Information Update: 06 May 2024
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms IMvigor130
- Sponsors Chugai Pharmaceutical; Roche
- 23 Apr 2024 Status changed from active, no longer recruiting to completed.
- 28 Mar 2024 This study has been Completed in Portugal, According to European Clinical Trials Database record.
- 08 Mar 2024 This study has been Completed in Netherlands, According to European Clinical Trials Database record.